G
Gerard M. Jensen
Publications - 6
Citations - 352
Gerard M. Jensen is an academic researcher. The author has contributed to research in topics: Amphotericin B & Aspergillosis. The author has an hindex of 6, co-authored 6 publications receiving 295 citations.
Papers
More filters
Journal ArticleDOI
The Viscoelastic Properties of the Fungal Cell Wall Allow Traffic of AmBisome as Intact Liposome Vesicles
Louise A. Walker,Prashant Sood,Megan D. Lenardon,Megan D. Lenardon,Gillian Milne,Jon A. Olson,Gerard M. Jensen,Julie M. Wolf,Arturo Casadevall,Jill Adler-Moore,Neil A. R. Gow +10 more
TL;DR: The fact that AmBisome can transit through chemically diverse cell wall matrices when these liposomes are larger than the theoretical cell wall porosity suggests that the wall is capable of rapid remodeling, which may also be the mechanism for release of extracellular vesicles.
Journal ArticleDOI
Comparative Efficacies, Toxicities, and Tissue Concentrations of Amphotericin B Lipid Formulations in a Murine Pulmonary Aspergillosis Model
TL;DR: Although both drugs were effective in prolonging survival in treatment of murine pulmonary aspergillosis, the reduced nephrotoxicity of L-AMB increased its therapeutic index, allowing for its safe and effective use at 15 or 20 mg/kg.
Journal ArticleDOI
Comparison of the Physicochemical, Antifungal, and Toxic Properties of Two Liposomal Amphotericin B Products
Jon A. Olson,Jill Adler-Moore,Gerard M. Jensen,Julie Schwartz,M. Cecilia Dignani,Richard T. Proffitt +5 more
TL;DR: The efficacy and toxicity of these two liposomal amphotericin B products were significantly different, and thus, the products were not comparable.
Journal ArticleDOI
Pharmacokinetics and Pharmacodynamics of Amphotericin B Deoxycholate, Liposomal Amphotericin B, and Amphotericin B Lipid Complex in an In Vitro Model of Invasive Pulmonary Aspergillosis
Jodi M. Lestner,Susan J. Howard,Joanne Goodwin,Lea Gregson,Jayesh Majithiya,Thomas J. Walsh,Gerard M. Jensen,William W. Hope +7 more
TL;DR: The pharmacodynamic and pharmacokinetic properties of amphotericin B (AmB) formulations against invasive pulmonary aspergillosis (IPA) are not well understood and the three most widely used formulations of AmB differ markedly within an in vitro lung model of IPA.
Journal ArticleDOI
Toxicity and efficacy differences between liposomal amphotericin B formulations in uninfected and Aspergillus fumigatus infected mice.
TL;DR: Given the differences in size, toxicity, and efficacy, AmBi and Lbn were not physically or functionally comparable, and these differences underscore the need for adequate testing when comparing amphotericin B liposome formulations.